BioCardia (BCDA) Stock Overview
A clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
BCDA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
BioCardia, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.39 |
| 52 Week High | US$3.20 |
| 52 Week Low | US$1.00 |
| Beta | 0.79 |
| 1 Month Change | -2.11% |
| 3 Month Change | -39.30% |
| 1 Year Change | -42.56% |
| 3 Year Change | -95.32% |
| 5 Year Change | -95.34% |
| Change since IPO | -99.32% |
Recent News & Updates
Recent updates
Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable
May 14
Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns
Oct 12BioCardia stock rises on contract for delivery products for BlueRock's cell therapies
Aug 24Will BioCardia (NASDAQ:BCDA) Spend Its Cash Wisely?
Aug 24Shareholder Returns
| BCDA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.1% | -0.3% | 2.0% |
| 1Y | -42.6% | 2.3% | 17.9% |
Return vs Industry: BCDA underperformed the US Biotechs industry which returned 2.5% over the past year.
Return vs Market: BCDA underperformed the US Market which returned 17.8% over the past year.
Price Volatility
| BCDA volatility | |
|---|---|
| BCDA Average Weekly Movement | 14.9% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BCDA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BCDA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 19 | Peter Altman | www.biocardia.com |
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company’s lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome.
BioCardia, Inc. Fundamentals Summary
| BCDA fundamental statistics | |
|---|---|
| Market cap | US$14.75m |
| Earnings (TTM) | -US$8.79m |
| Revenue (TTM) | n/a |
Is BCDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCDA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$5.24m |
| Gross Profit | -US$5.24m |
| Other Expenses | US$3.55m |
| Earnings | -US$8.79m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.83 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BCDA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/26 02:37 |
| End of Day Share Price | 2025/10/24 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioCardia, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Joseph Pantginis | H.C. Wainwright & Co. |